You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
HSP-70 ANTIBODY (ANTI-68 KD ANTIGEN) |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB1755 Geisinger Epic ID: 23453 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Serum | |
Preferred collection container: |
||
Alternate Collection Container: |
6 mL red-top (plain, non-serum separator) tube
|
|
Specimen required: |
1 mL aliquot serum; minimum 0.5 mL. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Centrifuge and aliquot. | |
Transport temperature: |
Room temperature. | |
Specimen stability: |
Room Temperature: 7 days. Refrigerated: 14 days. Frozen: 21 days. | |
Rejection criteria: |
Gross hemolysis, grossly lipemic | |
TEST DETAILS |
||
CPT code(s): |
84181 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
HSP-70 Antibody (Anti-68 KD Antigen). | |
Methodology: |
Western Blot |
|
Synonyms: |
68KD, Meniere's Disease, 68 Kilodalton Antigen, Sensorineural Hearing Loss (SNHL), Heat Shock Protein 70, Quest test code 36734
|
|
Clinical significance: |
Sensorineural hearing loss (SNHL), commonly referred to as nerve deafness, may be caused by genetic or acquired factors such as infections or can be immunologically mediated. A subgroup of idiopathic SNHL cases are treatable with immunosuppressive therapy. The laboratory work up to identify these cases should include serum antibody tests to 68kd inner ear antigen. Twenty-two percent of patients with bilateral rapidly progressive SNHL and 30% of the patients with Meniere's disease had antibodies that reacted with 68kd antigen present in the bovine inner ear extracts. Anti-68kd antibodies also occur in approximately 60% of patients with bilateral and 35% of patients with unilateral Meniere's Syndrome and 37% of patients with contralateral delayed endolymphatic hydrops. | |